| Primary |
|
| Leukoencephalopathy |
100.0% |
|
| Secondary |
| Product Used For Unknown Indication |
34.0% |
| Drug Use For Unknown Indication |
28.3% |
| Pain |
6.5% |
| Drug Exposure During Pregnancy |
4.6% |
| Anaesthesia |
4.1% |
| Premedication |
2.9% |
| Unevaluable Event |
2.7% |
| General Anaesthesia |
2.1% |
| Prophylaxis |
1.8% |
| Acute Myeloid Leukaemia |
1.7% |
| Migraine |
1.5% |
| Cholelithiasis |
1.2% |
| Hypertension |
1.2% |
| Surgery |
1.2% |
| Herpes Zoster |
1.1% |
| Induction Of Anaesthesia |
1.1% |
| Infection Prophylaxis |
1.1% |
| Antibiotic Therapy |
1.0% |
| Cholecystectomy |
1.0% |
| Influenza |
1.0% |
|
| Toxic Skin Eruption |
10.0% |
| Stevens-johnson Syndrome |
9.6% |
| Renal Failure Acute |
8.1% |
| Thrombocytopenia |
7.2% |
| Rash Maculo-papular |
6.2% |
| Pancreatitis Acute |
5.7% |
| Cytolytic Hepatitis |
5.3% |
| Status Epilepticus |
5.3% |
| Vomiting |
5.3% |
| Acute Generalised Exanthematous Pustulosis |
4.8% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Hypertriglyceridaemia |
3.8% |
| Generalised Erythema |
3.3% |
| Hyponatraemia |
3.3% |
| Hepatocellular Injury |
2.9% |
| Rash |
2.9% |
| Rash Pustular |
2.9% |
| Agranulocytosis |
2.4% |
| Anaphylactic Shock |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
36.5% |
| Drug Use For Unknown Indication |
20.1% |
| Pain |
9.2% |
| Prophylaxis |
5.2% |
| Thrombosis Prophylaxis |
3.3% |
| Anaesthesia |
3.1% |
| Anxiety |
2.4% |
| Hypertension |
2.0% |
| Rheumatoid Arthritis |
1.8% |
| Sciatica |
1.8% |
| Constipation |
1.7% |
| Nausea |
1.7% |
| Multiple Myeloma |
1.7% |
| Premedication |
1.6% |
| Lymphoma |
1.5% |
| Abdominal Pain |
1.4% |
| Acute Lymphocytic Leukaemia |
1.3% |
| Bone Pain |
1.3% |
| Hiv Infection |
1.3% |
| Acute Myeloid Leukaemia |
1.2% |
|
| Renal Failure Acute |
11.7% |
| Thrombocytopenia |
9.8% |
| Pyrexia |
7.2% |
| Hepatocellular Injury |
6.8% |
| Neutropenia |
6.0% |
| Renal Failure |
6.0% |
| Sepsis |
6.0% |
| Cytolytic Hepatitis |
5.3% |
| Toxic Epidermal Necrolysis |
4.9% |
| Vomiting |
4.9% |
| Weight Decreased |
4.9% |
| Pancreatitis Acute |
3.8% |
| Urticaria |
3.4% |
| Cholestasis |
3.0% |
| Hepatitis Cholestatic |
3.0% |
| Acute Generalised Exanthematous Pustulosis |
2.6% |
| Bacterial Sepsis |
2.6% |
| Paraesthesia |
2.6% |
| Pulmonary Embolism |
2.6% |
| Rash Maculo-papular |
2.6% |
|
| Interacting |
| Pain |
24.6% |
| Anxiety |
10.5% |
| Bipolar Ii Disorder |
10.5% |
| Insomnia |
10.5% |
| Analgesic Therapy |
7.0% |
| Drug Use For Unknown Indication |
7.0% |
| Hypertension |
5.3% |
| Spinal Compression Fracture |
5.3% |
| Depression |
3.5% |
| Nausea |
3.5% |
| Product Used For Unknown Indication |
3.5% |
| Essential Hypertension |
1.8% |
| Optic Neuritis |
1.8% |
| Procedural Pain |
1.8% |
| Prophylaxis |
1.8% |
| Thrombosis Prophylaxis |
1.8% |
|
| Drug Interaction |
18.2% |
| Insomnia |
18.2% |
| Urinary Retention |
18.2% |
| Anosognosia |
9.1% |
| Bipolar Disorder |
9.1% |
| Hyponatraemia |
9.1% |
| Logorrhoea |
9.1% |
| Off Label Use |
9.1% |
|
